Loading stock data…
Crinetics Pharmaceuticals (CRNX)
$83.73+0.08 (+0.10%)
Market ClosedLast close Jul 24
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crinetics Pharmaceuticals, Inc. in the Healthcare sector is trading at $83.73 with a market capitalization of $3.6B. Wall Street consensus targets $82.50 (10 analysts), implying a -1.5% move over the next 12 months. The stock is currently near its 52-week high of $84.00, remaining 85.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.73M↑ | $6.16M↑ | $143,000↓ | $1.03M↑ | $361,000 |
| Gross Profit | $10.53M | — | — | — | $361,000 |
| Operating Income | -$140.38M↓ | -$133.67M↑ | -$142.59M↓ | -$129.11M↓ | -$111.41M |
| Net Income | -$127.84M↓ | -$122.81M↑ | -$130.09M↓ | -$115.64M↓ | -$96.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.76%
Volume
Today's trading volume
2.32M
Recent News
Vertex was sole bidder in high-premium Crinetics acquisition
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.
Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals recently announced its largest-ever acquisition.